Recent developments include Heron's agreement to sell substantially all assets to CorMedix in a transaction involving cash, stock, royalties, and earn-outs, expected to close in early 2027. The company reported wider losses in Q2 2026 and withdrew 2026 guidance amid patent litigation over CINVANTI.

• On November 8, 2026, Heron Therapeutics entered into an Asset Purchase Agreement to sell substantially all its assets to CorMedix, excluding certain tax attributes, with consideration including cash, CorMedix common stock, royalties, and earn-out payments [S2].
• The Asset Sale is expected to close in the first quarter of 2027, subject to stockholder approval and customary closing conditions, after which Heron will exit its current biotechnology business but remain publicly traded [S2].
• Heron reported a wider net loss in Q2 2026 and withdrew its 2026 guidance amid ongoing patent litigation related to CINVANTI [N5].
• ZYNRELEF continues to benefit from CMS reimbursement policies under the NOPAIN Act, including a permanent J-code for separate Medicare reimbursement effective October 1, 2025 [S1].
• APONVIE received a permanent CMS J-code effective April 1, 2026, following expiration of its pass-through payment status [S1].
• Heron entered into a multi-product License Agreement with Long Grove Pharmaceuticals in September 2026 [S2].

Heron's portfolio includes innovative, FDA-approved products with unique formulations and reimbursement advantages, such as ZYNRELEF's extended-release local anesthetic status and APONVIE's rapid IV administration for PONV. The company's Biochronomer Technology offers a platform for sustained drug delivery, potentially enabling multimodal therapies. Extensive patent protection through the mid-2030s provides a barrier to entry. The recent asset sale agreement with CorMedix includes cash, stock, royalties, and earn-out payments, providing liquidity and potential future revenue streams. Post-sale, Heron plans to explore strategic transactions and investments, which could diversify its business and create new value opportunities.

Heron faces significant competition from larger pharmaceutical and biotechnology companies with more resources and experience. Patent litigation, such as the recent invalidation and non-infringement rulings related to CINVANTI, creates uncertainty around intellectual property protection. The company reported net losses and withdrew 2026 guidance amid ongoing litigation. The cessation of SUSTOL sales and the decision to sell substantially all assets indicate challenges in sustaining its current biotechnology operations. Post-transaction, the company's future business direction is uncertain, and execution risks exist in pursuing new strategic opportunities.

Heron's moat is supported by its proprietary Biochronomer Technology enabling sustained drug delivery, a portfolio of FDA-approved products with differentiated formulations such as CINVANTI's surfactant-free IV aprepitant, and extensive patent protection covering its products and technologies through the mid-2030s. The company's established relationships with healthcare providers and reimbursement positioning, including CMS policies favoring non-opioid pain management treatments, further contribute to its competitive positioning. However, the biotechnology and pharmaceutical markets are highly competitive with larger companies possessing greater resources, and patent litigation poses ongoing risks.

• Patent Litigation and Intellectual Property Risks: Recent court decisions invalidated certain patents and found no infringement on others related to CINVANTI, potentially weakening Heron's patent protection and competitive position.
• Competitive Market Environment: Heron operates in highly competitive markets with larger pharmaceutical and biotechnology companies that have greater financial and technical resources, which may limit Heron's market share and growth.
• Financial Performance and Guidance Uncertainty: The company reported net losses and withdrew its 2026 guidance amid patent litigation, indicating financial and operational uncertainties.
• Dependence on Third-Party Manufacturers: Heron relies on a limited number of third-party manufacturers for production, and supply interruptions or quality issues could delay commercialization or increase costs.
• Strategic Transition Risks: The planned asset sale to CorMedix and exit from current biotechnology operations introduce execution risks related to the transition and future strategic direction.

• Heron Therapeutics is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations for acute care and oncology patients [S1].
• The company’s acute care product portfolio includes ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam, approved by the FDA in May 2021 and commercially available since July 2021 [S1].
• ZYNRELEF has FDA-approved expanded indications and a permanent CMS J-code for separate Medicare reimbursement outside surgical bundles through at least December 31, 2027 [S1].
• APONVIE is an intravenous formulation of aprepitant for prevention of postoperative nausea and vomiting (PONV), FDA approved in September 2022 and commercially available since March 2023, with a permanent CMS J-code effective April 1, 2026 [S1].
• The oncology care product portfolio includes CINVANTI, an IV formulation of aprepitant for chemotherapy-induced nausea and vomiting (CINV), approved in November 2017 and commercially available since January 2018 [S1].
• CINVANTI is free of synthetic surfactants like polysorbate 80, differentiating it from competitors and has demonstrated bioequivalence and better tolerability compared to EMEND IV [S1].
• SUSTOL, an extended-release 5-HT3 receptor antagonist for nausea and vomiting prevention in chemotherapy, was FDA approved in August 2016 and commercially available until September 30, 2026, when sales ceased [S1].
• Heron’s proprietary Biochronomer Technology enables sustained release of pharmacological agents over days to weeks with a single administration [S1].
• The company relies on third-party manufacturers under long-term agreements and does not own manufacturing facilities [S1].
• Heron holds numerous U.S. and foreign patents covering its products and technologies, with key patents for CINVANTI, ZYNRELEF, APONVIE, and HTX-034 expiring between 2033 and 2036 [S1].
• The company faces competition from major pharmaceutical and biotechnology companies with more resources and experience, and its products compete with various branded and generic alternatives in postoperative pain management, PONV, and CINV markets [S1].
• On November 8, 2026, Heron entered into an Asset Purchase Agreement to sell substantially all its assets to CorMedix, excluding certain tax attributes and other assets, with consideration including cash, CorMedix stock, royalties, and earn-out payments [S2].
• The Asset Sale is expected to close in Q1 2027, subject to stockholder approval and customary conditions, after which Heron will exit its current biotechnology operations but remain publicly traded [S2].
• Following the Asset Sale, Heron intends to evaluate strategic transactions and opportunities including acquisitions, investments, and alliances in various business areas [S2].
• Heron entered a multi-product License Agreement with Long Grove Pharmaceuticals in September 2026 [S2].
• As of September 30, 2026, Heron had cash and equivalents of $11.6 million and current assets of $209.1 million against current liabilities of $89.8 million, resulting in a current ratio of 2.33 and a cash ratio of 2.61 [S2].
• For the three months ended September 30, 2026, Heron reported a net loss of $5.0 million and basic and diluted EPS of -$0.03 [S2].
• Heron withdrew its 2026 guidance amid ongoing patent litigation over CINVANTI and reported wider losses in Q2 2026 [N5].
• ZYNRELEF benefits from CMS reimbursement policies under the NOPAIN Act, supporting separate Medicare reimbursement for qualifying non-opioid pain management treatments [S1].
• Heron’s sales and marketing team is U.S.-based with 78 employees as of December 31, 2025, targeting acute care and oncology specialists and managing key account relationships [S1].